Online inquiry

IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7284MR)

This product GTTS-WQ7284MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CSF1R gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001288705.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1436
UniProt ID P07333
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7284MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4338MR IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BIW-8405
GTTS-WQ15431MR IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA TSR-033
GTTS-WQ368MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 20A11-9mer-ALB11
GTTS-WQ13229MR IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-05082566
GTTS-WQ8759MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IBI-101
GTTS-WQ4524MR IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-936558
GTTS-WQ3751MR IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BAY-1093884
GTTS-WQ12372MR IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA NEOD-001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW